Nature Reviews Cancer最新文献

You've got exosomes. 有外泌体。

IF 66.8 1区医学

Nature Reviews Cancer Pub Date : 2025-10-24 DOI: 10.1038/s41568-025-00887-8

Gabrielle Brewer

引用次数: 0

Mechanisms, challenges and opportunities for FLASH radiotherapy in cancer. 闪光放射治疗癌症的机制、挑战和机遇。

IF 78.5 1区医学

Nature Reviews Cancer Pub Date : 2025-10-24 DOI: 10.1038/s41568-025-00878-9

Marie-Catherine Vozenin,Pierre Montay-Gruel,Pelagia Tsoutsou,Charles L Limoli

{"title":"Mechanisms, challenges and opportunities for FLASH radiotherapy in cancer.","authors":"Marie-Catherine Vozenin,Pierre Montay-Gruel,Pelagia Tsoutsou,Charles L Limoli","doi":"10.1038/s41568-025-00878-9","DOIUrl":"https://doi.org/10.1038/s41568-025-00878-9","url":null,"abstract":"FLASH radiotherapy has the potential to improve both patient quality of life and outcomes by delivering radiation at ultrahigh dose rates to effectively target tumours while sparing healthy tissues. However, the differential sensitivity of healthy tissues versus tumours to FLASH radiotherapy remains unexplained. In this Perspective, we hypothesize that FLASH radiotherapy distinguishes healthy tissues from tumours based on subtle functional and structural biological differences. We identify commonalities present in the various healthy tissues that are spared by FLASH radiotherapy that might be lost during tumorigenesis. We also propose that a specific class of proteins, termed long-lived proteins, define a critical radiolytic target that are present in nearly every healthy tissue that is FLASH radiotherapy resistant yet are absent in tumours. We extend this structural hypothesis further by suggesting that tumour and extracellular matrix rigidity affects sensitivity to changes in radiotherapy dose rate, where more rigid and dense desmoplastic tumours are more sensitive to FLASH radiotherapy than those possessing more elasticity. Substantiating these concepts experimentally may provide a new and generalized mechanism of action of radiation effects and may therefore inform clinical trial designs by identifying those tumour subclasses expected to exhibit optimal responses to FLASH radiotherapy.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"1 1","pages":""},"PeriodicalIF":78.5,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145357804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the potential of FinnGen to advance cancer research. 释放FinnGen推进癌症研究的潜力。

IF 78.5 1区医学

Nature Reviews Cancer Pub Date : 2025-10-16 DOI: 10.1038/s41568-025-00885-w

Mervi Aavikko,Aoxing Liu,Mark Daly

引用次数: 0

Exploiting metabolic cell death for cancer therapy. 利用代谢细胞死亡治疗癌症。

IF 78.5 1区医学

Nature Reviews Cancer Pub Date : 2025-10-15 DOI: 10.1038/s41568-025-00879-8

Chao Mao,Dadi Jiang,Albert C Koong,Boyi Gan

引用次数: 0

Decoding ferroptosis for cancer therapy. 解码下垂铁用于癌症治疗。

IF 66.8 1区医学

Nature Reviews Cancer Pub Date : 2025-10-10 DOI: 10.1038/s41568-025-00864-1

Adam Wahida, Marcus Conrad

{"title":"Decoding ferroptosis for cancer therapy.","authors":"Adam Wahida, Marcus Conrad","doi":"10.1038/s41568-025-00864-1","DOIUrl":"https://doi.org/10.1038/s41568-025-00864-1","url":null,"abstract":"<p><p>Resisting cell death is a pivotal hallmark of cancer and one of several increasingly actionable functional capabilities acquired by cancer cells to sustain their malignant state. Since the early 2000s, the discovery of multiple regulated cell death programmes has intensified interest in targeting these maladaptive traits that cancer cells employ to resist cellular demise. Among these, ferroptosis - the lethal outcome of iron-dependent (phospho)lipid peroxidation - stands apart from other regulated cell death mechanisms, as it is persistently suppressed while lacking an activating signal. In cancer research, ferroptosis has garnered considerable attention, with growing evidence suggesting that its deregulation intersects with other hallmarks of malignancy, thus positioning it as a pleiotropic target. However, in the absence of approved ferroptosis-based drugs and despite substantial advances in understanding the metabolic manoeuvres of cancer cells to evade ferroptosis, its heralded translational value remains somewhat speculative at this stage. This Review reconciles the biochemical foundation of ferroptosis, the evidence supporting its role in cancer biology and the potential strategies for rationalizing targeted therapies to induce ferroptosis-prone states in malignancies. Building on this foundation, we explore contentious issues surrounding ferroptosis, including its implications for immunogenicity and redox imbalances in cancer. Finally, we address critical considerations such as therapeutic windows and biomarkers of ferroptosis, which are prerequisites for successful translation into clinical oncology.</p>","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":" ","pages":""},"PeriodicalIF":66.8,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145275494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment. 揭示癌症治疗中抗体-药物偶联物的分子和免疫学驱动因素。

IF 78.5 1区医学

Nature Reviews Cancer Pub Date : 2025-10-02 DOI: 10.1038/s41568-025-00869-w

Alfred Zippelius,Sara M Tolaney,Paolo Tarantino,Joseph P Balthasar,Greg M Thurber

{"title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment.","authors":"Alfred Zippelius,Sara M Tolaney,Paolo Tarantino,Joseph P Balthasar,Greg M Thurber","doi":"10.1038/s41568-025-00869-w","DOIUrl":"https://doi.org/10.1038/s41568-025-00869-w","url":null,"abstract":"After decades of investment, antibody-drug conjugates (ADCs) are finally demonstrating their potential, marked by a growing number of clinical approvals, applications in earlier lines of treatment and integration into drug combinations, including immunotherapies. This progress has spurred investment in developing new ADCs and expanding the use of approved ADCs in clinical practice. The design of ADCs is complex, involving multiple molecular components that interact with both tumour and host tissue microenvironments. In this Review, we explore the molecular and immunological factors influencing ADC efficacy and toxicity. We describe how the molecular components of ADCs determine their systemic, tissue and cellular distribution, which ultimately dictates therapeutic efficacy. These interactions also determine the toxicity profile and set limitations on maximum dosing. Finally, we discuss the impact of ADC treatment on immune cells, emphasizing the distinct but interconnected roles of immunogenic cell death, activation of immune cells such as dendritic cells and antibody-Fc interactions. These mechanisms are crucial for increasing efficacy beyond the direct cytotoxic effects of the payload. By providing insights into the intricate interactions of ADCs, this Review aims to inform the rational design of combination therapies and guide the development of the next generation of clinically effective ADCs.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"13 1","pages":""},"PeriodicalIF":78.5,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145209077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tamoxifen takes the wheel 他莫昔芬起作用。

IF 66.8 1区医学

Nature Reviews Cancer Pub Date : 2025-09-26 DOI: 10.1038/s41568-025-00881-0

Daniela Senft

引用次数: 0

Unlocking the potential of urine-based liquid biopsy through improved reporting and standardization. 通过改进报告和标准化，释放尿液液体活检的潜力。

IF 78.5 1区医学

Nature Reviews Cancer Pub Date : 2025-09-25 DOI: 10.1038/s41568-025-00882-z

Douglas G Ward,Richard T Bryan,Aadel A Chaudhuri,James Hadfield,Jennifer Perez-Boza,Renske D M Steenbergen,Diana M Vega,Jennifer Whiting,Alexander W Wyatt,Lars Dyrskjøt

引用次数: 0

Identification, functional insights and therapeutic targeting of EMT tumour states. EMT肿瘤状态的识别、功能洞察和治疗靶向。

IF 78.5 1区医学

Nature Reviews Cancer Pub Date : 2025-09-25 DOI: 10.1038/s41568-025-00873-0

Anqi Dong,Cédric Blanpain

引用次数: 0

Focusing on the complex and dynamic interplay between ageing and cancer 专注于衰老和癌症之间复杂而动态的相互作用

IF 66.8 1区医学

Nature Reviews Cancer Pub Date : 2025-09-24 DOI: 10.1038/s41568-025-00870-3

引用次数: 0